These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 30853815)

  • 61. Quality of evidence considered by Health Canada in granting full market authorisation to new drugs with a conditional approval: a retrospective cohort study.
    Lexchin J
    BMJ Open; 2018 Apr; 8(4):e020377. PubMed ID: 29705760
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Perspectives on Cost and Value in Cancer Care.
    Saltz LB
    JAMA Oncol; 2016 Jan; 2(1):19-21. PubMed ID: 26501848
    [No Abstract]   [Full Text] [Related]  

  • 63. Minimalism in oncology.
    The Lancet Oncology
    Lancet Oncol; 2018 May; 19(5):579. PubMed ID: 29726372
    [No Abstract]   [Full Text] [Related]  

  • 64. The ESMO-Magnitude of Clinical Benefit Scale for novel oncology drugs: correspondence with three years of reimbursement decisions in Israel.
    Hammerman A; Greenberg-Dotan S; Feldhamer I; Birnbaum Y; Cherny NI
    Expert Rev Pharmacoecon Outcomes Res; 2018 Feb; 18(1):119-122. PubMed ID: 28617621
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Confirmatory versus explorative endpoint analysis: Decision-making on the basis of evidence available from market authorization and early benefit assessment for oncology drugs.
    Niehaus I; Dintsios CM
    Health Policy; 2018 Jun; 122(6):599-606. PubMed ID: 29605527
    [TBL] [Abstract][Full Text] [Related]  

  • 66. "There is always a better way": Managing uncertainty in decision making about new cancer drugs in Canada.
    Driedger SM; Cooper E; Annable G; Brouwers M
    Int J Health Plann Manage; 2018 Apr; 33(2):e485-e499. PubMed ID: 29417619
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Targeted immunotherapies overtaking emerging oncology market value based growth.
    Jakovljevic MB
    J BUON; 2015; 20(1):350-1. PubMed ID: 25778340
    [No Abstract]   [Full Text] [Related]  

  • 68. Health technology assessment of drugs for rare diseases: insights, trends, and reasons for negative recommendations from the CADTH common drug review.
    Janoudi G; Amegatse W; McIntosh B; Sehgal C; Richter T
    Orphanet J Rare Dis; 2016 Dec; 11(1):164. PubMed ID: 27908281
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Conditional Drug Approval as a Path to Market for Oncology Drugs in Canada: Challenges and Recommendations for Assessing Eligibility and Regulatory Responsiveness.
    McPhail M; Weiss E; Bubela T
    Front Med (Lausanne); 2021; 8():818647. PubMed ID: 35186979
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Time to Entry for New Cancer Medicines: From European Union-Wide Marketing Authorization to Patient Access in Belgium, Estonia, Scotland, and Sweden.
    Ferrario A
    Value Health; 2018 Jul; 21(7):809-821. PubMed ID: 30005753
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Drug pricing and value in oncology.
    Danzon PM; Taylor E
    Oncologist; 2010; 15 Suppl 1():24-31. PubMed ID: 20237214
    [TBL] [Abstract][Full Text] [Related]  

  • 72. [Benefit-risk evaluation of new drugs as a basis for decisions on prioritization in hematology/oncology: methodical challenges and problem-solving strategies].
    Ludwig WD; Schildmann J
    Onkologie; 2011; 34 Suppl 1():6-10. PubMed ID: 21389762
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Conditional Funding Recommendations for Drugs in Canada: A Cross-Sectional Analysis.
    Graili P
    Appl Health Econ Health Policy; 2023 Jul; 21(4):673-681. PubMed ID: 36609982
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Trade-offs, fairness, and funding for cancer drugs: key findings from a deliberative public engagement event in British Columbia, Canada.
    Bentley C; Costa S; Burgess MM; Regier D; McTaggart-Cowan H; Peacock SJ
    BMC Health Serv Res; 2018 May; 18(1):339. PubMed ID: 29739463
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Does conditional approval for new oncology drugs in Europe lead to differences in health technology assessment decisions?
    Lipska I; Hoekman J; McAuslane N; Leufkens HG; Hövels AM
    Clin Pharmacol Ther; 2015 Nov; 98(5):489-91. PubMed ID: 26250656
    [TBL] [Abstract][Full Text] [Related]  

  • 76. National reimbursement listing determinants of new cancer drugs: a retrospective analysis of 58 cancer treatment appraisals in 2007-2016 in South Korea.
    Kim ES; Kim JA; Lee EK
    Expert Rev Pharmacoecon Outcomes Res; 2017 Aug; 17(4):401-409. PubMed ID: 28010146
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Meaningful patient representation informing Canada's cancer drug funding decisions: views of patient representatives on the Pan-Canadian Oncology Drug Review.
    Hoch JS; Brown MB; McMahon C; Nanson J; Rozmovits L
    Curr Oncol; 2014 Oct; 21(5):263-6. PubMed ID: 25302034
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Public perspectives on disinvestments in drug funding: results from a Canadian deliberative public engagement event on cancer drugs.
    Costa S; Bentley C; Regier DA; McTaggart-Cowan H; Mitton C; Burgess MM; Peacock SJ
    BMC Public Health; 2019 Jul; 19(1):977. PubMed ID: 31331312
    [TBL] [Abstract][Full Text] [Related]  

  • 79. The shortage of essential chemotherapy drugs in the United States.
    Gatesman ML; Smith TJ
    N Engl J Med; 2011 Nov; 365(18):1653-5. PubMed ID: 22040130
    [No Abstract]   [Full Text] [Related]  

  • 80. Cost-effectiveness of ceritinib in patients previously treated with crizotinib in anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer in Canada.
    Hurry M; Zhou ZY; Zhang J; Zhang C; Fan L; Rebeira M; Xie J
    J Med Econ; 2016 Oct; 19(10):936-44. PubMed ID: 27149298
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.